{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:34:48Z","timestamp":1767591288320,"version":"3.48.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), with approximately 20\u201330% of LN patients progressing to end-stage renal disease (ESRD) within a decade. Persistent extra-renal SLE activity, cardiovascular events, and infections significantly contribute to adverse outcomes. Current therapeutic strategies primarily rely on glucocorticoids and immunosuppressants; however, the adverse effects of these agents are intensified in ESRD patients. Belimumab, a B-lymphocyte-targeted biologic agent, has demonstrated efficacy in managing SLE but lacks sufficient data regarding its application in ESRD-LN patients. This study aims to evaluate the role of belimumab in controlling extra-renal disease activity, optimizing medication use, and assessing safety in ESRD-LN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective analysis involved eight LN patients with ESRD (eGFR &amp;lt;15\u202fmL\/min\/1.73\u202fm\n                      <jats:sup>2<\/jats:sup>\n                      or on hemodialysis) who received belimumab treatment. Data on SLE manifestations, medications, and laboratory parameters were collected before and after ESRD onset. The primary endpoints included changes in extra-renal Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, adjustments in prednisone dosages, and the incidence of infection episodes during belimumab therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study analyzed data from eight ESRD-LN patients treated with belimumab over a median follow-up period of 28.01\u202f\u00b1\u202f14.57\u202fmonths. Belimumab significantly reduced extra-renal SLEDAI scores (from 6.13\u202f\u00b1\u202f3.09 to 1.50\u202f\u00b1\u202f1.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01) and improved complement C3 levels (from 0.64\u202f\u00b1\u202f0.12\u202fg\/L to 0.8\u202f\u00b1\u202f0.16\u202fg\/L). Glucocorticoid dosages were markedly reduced (from 21.25\u202f\u00b1\u202f9.64\u202fmg\/day to 3.91\u202f\u00b1\u202f3.98\u202fmg\/day), with three patients discontinuing glucocorticoid therapy entirely. Mild infections were observed, but no severe infections requiring mechanical ventilation were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Belimumab appears to be a promising therapeutic option for ESRD-LN patients, effectively controlling extra-renal disease activity, reducing glucocorticoid use, and demonstrating a favorable safety profile. Further research is required to optimize dosing strategies and to validate the long-term efficacy and safety of belimumab in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1717280","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:29:58Z","timestamp":1767590998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of belimumab on extra-renal lupus in patients with lupus nephritis and end-stage renal disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Jia-Qi","family":"Teng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Hua","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"ref1","volume-title":"Compilation Group of Guidelines for the diagnosis and treatment of lupus nephritis in China Chinese guidelines for the diagnosis and treatment of lupus nephritis","year":""},{"key":"ref2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Richard","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/ndt\/gfad167","article-title":"Effect of belimumab on kid-neyrelated outcomes in patients with lupus nephritis: post hoc sub- group analyses of the phase 3 BLISS-LNtrial","volume":"38","author":"Hans-Joachim","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the east Asian population","volume":"81","author":"Xueqing","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"1: kidney disease: improving global outcomes (KDIGO) lupus nephritis work group. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000529675","article-title":"Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China","volume":"22","author":"Meng","year":"2023","journal-title":"Kidney Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial","volume":"377","author":"Sandra","year":"2011","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1177\/09612033221119123","article-title":"Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy","volume":"31","author":"Diankun","year":"2022","journal-title":"Lupus"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"977377","DOI":"10.3389\/fimmu.2022.977377","article-title":"Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: a case report and literature review","volume":"13","author":"Chengning","year":"2022","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/RHU.0000000000002018","article-title":"Clinical use of Belimumab for systemic lupus erythematosus in the setting of advanced chronic kidney disease and end-stage kidney disease on Dialysis: a case series. JCR","volume":"30","author":"Matthew","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40620-020-00706-3","article-title":"Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient)","volume":"33","author":"Valentina","year":"2020","journal-title":"J Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000512585","article-title":"Successful treatment with Belimumab in a patient with refractory systemic lupus erythematosus after initiation of hemodialysis: considering the synergistic effect of Belimumab and immunological burn-out phenomenon in end-stage renal disease patients on hemodialysis","volume":"51","author":"Kazunori","year":"2022","journal-title":"Blood Purif"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/rheumatology\/kev349","article-title":"Risk factors for systemic lupus erythematosus flares in patients with end-stage renal disease: a case-control study","volume":"55","author":"Barrera-Vargas","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s12882-020-02083-2","article-title":"Systemic lupus erythematosus activity and hydroxychloroquine use before and after end-stage renal disease","volume":"21","author":"Salgado Guerrero","year":"2020","journal-title":"BMC Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3899\/jrheum.220101","article-title":"Disease flare of systemic lupus erythematosus in patients with Endstage renal disease on Dialysis","volume":"49","author":"Kim","year":"2022","journal-title":"J Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMoa021583","article-title":"Effect of dialysis dose and membrane flux in maintenance hemodialysis","volume":"347","author":"Eknoyan","year":"2002","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/1744666X.2018.1538789","article-title":"Mortality in systemic lupus erythematosus: causes, predictors and interventions","volume":"14","author":"Ocampo-Piraquive","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"ref21","volume-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","year":"2017"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1717280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:29:59Z","timestamp":1767590999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1717280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":21,"alternative-id":["10.3389\/fmed.2025.1717280"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1717280","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1717280"}}